Literature DB >> 19506808

[Diagnosis and causal treatment of sepsis].

F M Brunkhorst1, K Reinhart.   

Abstract

The high mortality and morbidity of severe sepsis and septic shock had not been reduced during the two recent decades, despite a number of advances in the field of supportive and adjunctive sepsis therapies. The reason might be that important steps towards overcoming of sepsis - early diagnosis, the surgical resection of the infectious focus and an adequate antibiotic treatment - at present are still suboptimal and have to be improved. However, worldwide growing resistances of pathogens against the common antibiotics are detected. In opposite, no major progress in the development of new antibiotics, mainly for the treatment of Gram-negative non-fermenter infections like Pseudomonas aeruginosa, can be predicted for the next years. Therefore, sepsis treatment must be focused on prevention of infection, and on an optimised application of current antibiotic substances. The key factors are a broad, high dose, and early applicated initial treatment, a de-escalation strategy according to the clinical course supported by the application of novel molecular markers, and - with exceptions - a limitation of treatment to 7 to 10 days. A closer cooperation between microbiologists, infection control specialists and clinical infectious disease consultants may be a key factor to overcome the raising problems in the future.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506808     DOI: 10.1007/s00108-008-2287-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  20 in total

Review 1.  Update on detection of bacteremia and fungemia.

Authors:  L G Reimer; M L Wilson; M P Weinstein
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Authors:  Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

3.  [The value of different lavage treatment patterns in diffuse peritonitis].

Authors:  P Kujath; C Eckmann; H Esnaashari; H-P Bruch
Journal:  Zentralbl Chir       Date:  2007-10       Impact factor: 0.942

Review 4.  Clinical relevance of new diagnostic methods for bloodstream infections.

Authors:  Jacques Schrenzel
Journal:  Int J Antimicrob Agents       Date:  2007-09-19       Impact factor: 5.283

5.  Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.

Authors:  Scott T Micek; Ann E Lloyd; David J Ritchie; Richard M Reichley; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

6.  Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.

Authors:  S Harbarth; K Holeckova; C Froidevaux; D Pittet; B Ricou; G E Grau; L Vadas; J Pugin
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

7.  Epidemiology of sepsis in Germany: results from a national prospective multicenter study.

Authors:  Christoph Engel; Frank M Brunkhorst; Hans-Georg Bone; Reinhard Brunkhorst; Herwig Gerlach; Stefan Grond; Matthias Gruendling; Guenter Huhle; Ulrich Jaschinski; Stefan John; Konstantin Mayer; Michael Oppert; Derk Olthoff; Michael Quintel; Max Ragaller; Rolf Rossaint; Frank Stuber; Norbert Weiler; Tobias Welte; Holger Bogatsch; Christiane Hartog; Markus Loeffler; Konrad Reinhart
Journal:  Intensive Care Med       Date:  2007-02-24       Impact factor: 17.440

Review 8.  [Diagnosis and therapy of sepsis. Guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine].

Authors:  K Reinhart; F Brunkhorst; H Bone; H Gerlach; M Gründling; G Kreymann; P Kujath; G Marggraf; K Mayer; A Meier-Hellmann; C Peckelsen; C Putensen; M Quintel; M Ragaller; R Rossaint; F Stüber; N Weiler; T Welte; K Werdan
Journal:  Internist (Berl)       Date:  2006-04       Impact factor: 0.743

9.  Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.

Authors:  Philip S Barie; Mark D Williams; Jill Shwed McCollam; Becky M Bates; Rebecca L Qualy; Stephen F Lowry; Donald E Fry
Journal:  Am J Surg       Date:  2004-09       Impact factor: 2.565

10.  Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.

Authors:  Nasia Safdar; Jo Handelsman; Dennis G Maki
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

View more
  12 in total

Review 1.  [Urosepsis and treatment].

Authors:  F M E Wagenlehner; C Lichtenstern; M A Weigand; W Weidner
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

2.  [Treatment of invasive mycoses. What can be done when therapy fails?].

Authors:  F Bloos
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

3.  Unveiling differentially expressed genes upon regulation of transcription factors in sepsis.

Authors:  Junli Zhang; Yuelei Cheng; Minmin Duan; Nannan Qi; Jian Liu
Journal:  3 Biotech       Date:  2017-04-25       Impact factor: 2.406

4.  [Impairment of oxygenation of patients in surgical intensive care : Early symptom of severe sepsis].

Authors:  M Hückstädt; G O Hofmann; T Mendel; R Stuttmann; P Hilbert-Carius
Journal:  Anaesthesist       Date:  2016-10-05       Impact factor: 1.041

5.  [Prevention and follow-up care of sepsis. 1st revision of S2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V., DSG) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin, DIVI)].

Authors:  F M Brunkhorst; P Gastmeier; W Kern; W Krüger; K Mayer; A Weimann; T Welte; C Putensen; K Werdan; K Reinhart
Journal:  Internist (Berl)       Date:  2010-07       Impact factor: 0.743

Review 6.  [Prevention of periprosthetic joint infections].

Authors:  Norbert Harrasser; Tobias Harnoss
Journal:  Wien Med Wochenschr       Date:  2012-02-16

7.  [Sepsis : putting knowledge into practice].

Authors:  S N Stehr; I Woest; C S Hartog; K Reinhart
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

8.  Propofol inhibits the activation of p38 through up-regulating the expression of annexin A1 to exert its anti-inflammation effect.

Authors:  Jing Tang; Xi Chen; Weifeng Tu; Yuanbo Guo; Zhenlong Zhao; Qiong Xue; Chunshui Lin; Jinfang Xiao; Xuegang Sun; Tao Tao; Miaoning Gu; Youtan Liu
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

9.  The activation of EGFR promotes myocardial tumor necrosis factor-α production and cardiac failure in endotoxemia.

Authors:  Xuegang Sun; Jiani Liang; Xueqing Yao; Chunhua Lu; Tianyu Zhong; Xiaoyang Hong; Xiaofei Wang; Wenjuan Xu; Miaoning Gu; Jing Tang
Journal:  Oncotarget       Date:  2015-11-03

10.  Propofol protects against endotoxin-induced myocardial injury by inhibiting NF-κB-mediated inflammation.

Authors:  Zhijun Yang; Feng Cheng; Guosheng Yan; Lang Xiong; Huizhang Liu
Journal:  Exp Ther Med       Date:  2017-12-07       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.